Ameriprise Financial Inc Akebia Therapeutics, Inc. Transaction History

Ameriprise Financial Inc

$381 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.58 $358 - $832	-1,435 Reduced 0.87%	163,400 $94,000
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $46,091 - $70,673	153,637 Added 1372.0%	164,835 $52,000
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.67 $3,583 - $7,502	11,198 New	11,198 $4,000
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $7,595 - $30,908	-10,549 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $10,730 - $15,858	-4,748 Reduced 31.04%	10,549 $24,000
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $93,013 - $153,570	-39,580 Reduced 72.12%	15,297 $44,000
Q2 2021 Aug 16, 2021	BUY	$2.83 - $4.2 $97,295 - $144,396	34,380 Added 167.73%	54,877 $208,000
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $8,812 - $15,271	3,018 Added 17.27%	20,497 $69,000
Q4 2020 Feb 12, 2021	BUY	$2.22 - $3.78 $934 - $1,591	421 Added 2.47%	17,479 $49,000
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $278,929 - $1.53 Million	-116,707 Reduced 87.25%	17,058 $43,000
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $632,509 - $1.29 Million	94,829 Added 243.55%	133,765 $1.82 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $5,166 - $12,902	1,260 Added 3.34%	38,936 $295,000
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $9,085 - $19,348	2,875 Added 8.26%	37,676 $238,000
Q3 2019 Nov 14, 2019	BUY	$3.55 - $5.4 $20,749 - $31,563	5,845 Added 20.19%	34,801 $133,000
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $145,140 - $284,970	-35,400 Reduced 55.01%	28,956 $140,000
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $777,600 - $1.25 Million	-143,734 Reduced 69.07%	64,356 $527,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $925,818 - $1.57 Million	171,766 Added 472.87%	208,090 $1.15 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $124,545 - $178,281	16,740 Added 85.48%	36,324 $321,000
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $613,004 - $759,723	-66,995 Reduced 77.38%	19,584 $196,000
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $777,905 - $1.28 Million	-81,627 Reduced 48.53%	86,579 $825,000
Q4 2017 Feb 12, 2018	BUY	$14.24 - $19.59 $166,693 - $229,320	11,706 Added 7.48%	168,206 $2.5 Million
Q3 2017 Nov 07, 2017	BUY	$13.06 - $19.67 $2.04 Million - $3.08 Million	156,500	156,500 $3.08 Million

Others Institutions Holding AKBA

# of Institutions

120

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

Black Rock Inc. New York, NY

11.6M
Shares

$20.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.1M
Shares

$17.7 Million
0.0% of portfolio
Satter Management Co., L.P.

5.75M
Shares

$10.1 Million
13.23% of portfolio
Geode Capital Management, LLC Boston, MA

4.75M
Shares

$8.37 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

3.72M
Shares

$6.54 Million
0.01% of portfolio

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account